CN1070698C - 医药治疗 - Google Patents

医药治疗 Download PDF

Info

Publication number
CN1070698C
CN1070698C CN95192226A CN95192226A CN1070698C CN 1070698 C CN1070698 C CN 1070698C CN 95192226 A CN95192226 A CN 95192226A CN 95192226 A CN95192226 A CN 95192226A CN 1070698 C CN1070698 C CN 1070698C
Authority
CN
China
Prior art keywords
glucose tolerance
chemical compound
formula
application
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95192226A
Other languages
English (en)
Chinese (zh)
Other versions
CN1144479A (zh
Inventor
R·瓦加斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Ltd By Share Ltd
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1070698(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of CN1144479A publication Critical patent/CN1144479A/zh
Application granted granted Critical
Publication of CN1070698C publication Critical patent/CN1070698C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Lubricants (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN95192226A 1994-02-03 1995-02-03 医药治疗 Expired - Fee Related CN1070698C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/190,924 1994-02-03
US08/190,924 US5459164A (en) 1994-02-03 1994-02-03 Medical treatment

Publications (2)

Publication Number Publication Date
CN1144479A CN1144479A (zh) 1997-03-05
CN1070698C true CN1070698C (zh) 2001-09-12

Family

ID=22703362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95192226A Expired - Fee Related CN1070698C (zh) 1994-02-03 1995-02-03 医药治疗

Country Status (17)

Country Link
US (2) US5459164A (enExample)
EP (1) EP0814788B1 (enExample)
JP (1) JPH10503166A (enExample)
KR (1) KR100339874B1 (enExample)
CN (1) CN1070698C (enExample)
AT (1) ATE205390T1 (enExample)
AU (1) AU694761B2 (enExample)
CA (1) CA2182620C (enExample)
DE (1) DE69522716T2 (enExample)
DK (1) DK0814788T3 (enExample)
ES (1) ES2166817T3 (enExample)
IL (1) IL112515A (enExample)
PH (1) PH31220A (enExample)
PT (1) PT814788E (enExample)
TW (1) TW314466B (enExample)
WO (1) WO1995020949A1 (enExample)
ZA (1) ZA95814B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
TR200102699T2 (tr) * 1999-03-19 2002-03-21 Knoll Gmbh Kronik mafsal bozukluĞunun (osteoarthritis) tedavisi
KR20010113765A (ko) * 1999-03-19 2001-12-28 독터. 호르스트 하스칼, 잉에 린스 체중 증가와 관련된 특정 암의 치료방법
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
AU3895300A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
BR0009159A (pt) * 1999-03-19 2001-12-26 Knoll Gmbh Método de controle do ganho de peso associadocom drogas terapêuticas
AU3760900A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of menstrual function
AU3894500A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6403650B1 (en) * 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
CA2367022A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sleep apnoea
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
EP1165060A4 (en) * 1999-03-19 2002-06-12 Knoll Gmbh PROCESSING OF BILARIAL CALCULATIONS
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
WO2000056315A1 (en) * 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of pain
AU3894600A (en) * 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Method of treating sexual dysfunction
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
JP2008526836A (ja) 2005-01-06 2008-07-24 シージェー チェイルジェダン コーポレーション シブトラミンの無機酸塩
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339280A2 (en) * 1988-03-31 1989-11-02 The Boots Company PLC Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
EP0294028B1 (en) * 1987-05-04 1993-09-01 Eli Lilly And Company Fluoxetine useful for the treatment of diabetes
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339280A2 (en) * 1988-03-31 1989-11-02 The Boots Company PLC Use of N,N-dimethyl-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine for treatment of cerebral disorders

Also Published As

Publication number Publication date
ES2166817T3 (es) 2002-05-01
CN1144479A (zh) 1997-03-05
DE69522716D1 (de) 2001-10-18
DK0814788T3 (da) 2001-11-19
TW314466B (enExample) 1997-09-01
EP0814788A4 (en) 1999-05-06
AU1736295A (en) 1995-08-21
WO1995020949A1 (en) 1995-08-10
IL112515A0 (en) 1995-12-08
KR100339874B1 (ko) 2002-11-22
EP0814788B1 (en) 2001-09-12
PT814788E (pt) 2002-03-28
ZA95814B (en) 1995-08-03
US5942549A (en) 1999-08-24
IL112515A (en) 2000-07-26
US5459164A (en) 1995-10-17
PH31220A (en) 1998-05-05
EP0814788A1 (en) 1998-01-07
AU694761B2 (en) 1998-07-30
JPH10503166A (ja) 1998-03-24
DE69522716T2 (de) 2002-05-29
CA2182620A1 (en) 1995-08-10
ATE205390T1 (de) 2001-09-15
CA2182620C (en) 2007-01-16

Similar Documents

Publication Publication Date Title
CN1070698C (zh) 医药治疗
CN1188120C (zh) 治疗饮食紊乱的方法
AU724488B2 (en) Use of sibutramine analogues to prevent the development of diabetes
KR100573333B1 (ko) 지질 수준 저하를 위한 시부트라민 동족체의 용도
EP1039900B1 (en) Pharmaceutical composition containing sibutramine and orlistat
CN1231604A (zh) 医药治疗
WO2000056318A1 (en) Treatment of neuropathic pain or fibromyalgia
WO2000056313A1 (en) Method of controlling weight gain associated with therapeutic drugs
KR20020015357A (ko) 시부트라민 및 올리스타트를 포함하는 제약 조성물
WO2000056148A1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
EP1169027A1 (en) Treatment of osteoarthritis
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
HK1034446B (en) Therapeutic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: KNOELL GMBH

Free format text: FORMER NAME OR ADDRESS: KNOLL AG

Owner name: ABBOTT SHARES LIMITED KG CO., LTD.

Free format text: FORMER NAME OR ADDRESS: ABBOT CO., LTD.

Owner name: ABBOT CO., LTD.

Free format text: FORMER NAME OR ADDRESS: KNOELL GMBH

CP01 Change in the name or title of a patent holder

Patentee after: ABBOTT GmbH & Co.KG

Patentee before: Abbott Limited by Share Ltd.

Address after: Wiesbaden, Federal Republic of Germany

Patentee after: Abbott Limited by Share Ltd.

Address before: Ludwigshafen, Federal Republic of Germany

Patentee before: KNOLL GmbH

Patentee after: KNOLL GmbH

Patentee before: KNORR-BREMSE GmbH

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee